As filed
with the Securities and Exchange Commission on August 14, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
38-3317208 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
30142 S. Wixom Road
Wixom, Michigan 48393
(248) 960-9009
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
Rockwell Medical, Inc. Amended and Restated
2018 Long Term Incentive Plan
(Full title of the plans)
Mark Strobeck, Ph.D.
President and Chief Executive Officer
Rockwell Medical, Inc.
30142 S. Wixom Road
Wixom, Michigan 48393
(248) 960-9009
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Ryan A. Murr
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
(415) 393-8200 |
​ |
Megan C. Timmins
EVP, Chief Legal Officer and Secretary
Rockwell Medical, Inc.
30142 S. Wixom Road
Wixom, Michigan 48393
(248) 960-9009 |
Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
¨ |
|
Accelerated filer |
¨ |
|
|
|
|
Non-accelerated filer |
x |
|
Smaller reporting company |
x |
|
|
|
|
|
|
|
Emerging growth company |
¨ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 is
being filed to register an additional 5,000,000 shares of Rockwell Medical, Inc. (the “Company” or the “Registrant”)
common stock, par value $0.0001, issuable under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan. The
information contained in the Registrant’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission
on September 14, 2018 (File No. 333-227365), June 2, 2020 (File No. 333-238889), August 16, 2022 (File No. 333-266892),
and August 15, 2023 (File No. 333-273985), together with all exhibits filed therewith or incorporated therein by reference,
is hereby incorporated by reference pursuant to General Instruction E to Form S-8.
Exhibit No. |
|
Description |
|
|
4.1 |
|
Certificate of Incorporation,
effective as of August 30, 2019 (incorporated by reference to Exhibit 3.3 to the Company’s Form 8-K filed August 30,
2019). |
|
|
|
4.2 |
|
Certificate of Amendment
to Certificate of Incorporation of Rockwell Medical, Inc., dated May 12, 2022 (incorporated by reference to Exhibit 3.1
to the Company’s Form 8-K filed May 13, 2022). |
|
|
|
4.3 |
|
Amended
and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q filed November 14, 2022). |
|
|
|
5.1* |
|
Opinion of Gibson,
Dunn & Crutcher LLP. |
|
|
23.1* |
|
Consent of Independent
Registered Public Accounting Firm. |
|
|
|
23.2* |
|
Consent of Gibson,
Dunn & Crutcher LLP (contained in Exhibit 5.1). |
|
|
24.1* |
|
Power of Attorney (included
in signature page to this Registration Statement) |
|
|
|
99.1 |
|
Rockwell Medical, Inc.
Amended and Restated 2018 Long Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s
Form 10-Q filed August 14, 2025). |
|
|
|
107.1* |
|
Calculation of Filing Fee
Table. |
*Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Wixom, State of Michigan, on this 14th day of August, 2025.
|
ROCKWELL MEDICAL, INC. |
|
|
|
|
By: |
/s/ Mark Strobeck |
|
|
Name: Mark Strobeck, Ph.D. |
|
|
Title: President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person
whose signature appears below hereby constitutes and appoints Mark Strobeck, Ph.D. and Megan Timmins, and each of them acting individually,
as his or her attorney-in-fact, with full power of substitution, for him or her and in any and all capacities, to sign any and all amendments
to this Registration Statement on Form S-8 (including any post-effective amendments thereto) and to file the same, with all
exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming
all that each of said attorneys-in-fact, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on
the dates indicated.
Name
and Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Mark Strobeck
|
|
President, Chief Executive Officer and Director |
|
August 14,
2025 |
Mark Strobeck, Ph.D. |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Jesse Neri |
|
Senior
Vice President, Chief Financial Officer |
|
August 14,
2025 |
Jesse Neri |
|
(Principal Financial Officer) |
|
|
|
|
|
|
|
/s/ Nicholas Fanslau |
|
Controller |
|
August 14,
2025 |
Nicholas Fanslau |
|
(Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ Robert S. Radie |
|
Director
and Chairman of the Board |
|
August 14,
2025 |
Robert S. Radie |
|
|
|
|
|
|
|
|
|
/s/ John G. Cooper |
|
Director |
|
August 14,
2025 |
John G. Cooper |
|
|
|
|
|
|
|
|
|
/s/ Joan Lau |
|
Director |
|
August 14,
2025 |
Joan Lau, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Allen Nissenson |
|
Director |
|
August 14, 2025 |
Allen Nissenson, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Mark H. Ravich |
|
Director |
|
August 14, 2025 |
Mark H. Ravich |
|
|
|
|
|
|
|
|
|
/s/ Andrea Heslin Smiley |
|
Director |
|
August 14, 2025 |
Andrea Heslin Smiley |
|
|
|
|